Orgenesis Correlations
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
The current 90-days correlation between Orgenesis and Tff Pharmaceuticals is 0.1 (i.e., Average diversification). The correlation of Orgenesis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Orgenesis Correlation With Market
Weak diversification
The correlation between Orgenesis and DJI is 0.32 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Orgenesis and DJI in the same portfolio, assuming nothing else is changed.
Orgenesis |
The ability to find closely correlated positions to Orgenesis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Orgenesis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Orgenesis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Orgenesis to buy it.
Moving together with Orgenesis OTC Stock
| 0.72 | DWTX | Dogwood Therapeutics, Symbol Change | PairCorr |
| 0.69 | EMMA | Emmaus Life Sciences | PairCorr |
| 0.68 | IRD | Opus Genetics, Symbol Change | PairCorr |
| 0.66 | CYCCP | Cyclacel Pharmaceuticals | PairCorr |
| 0.77 | ZBIO | Zenas BioPharma, Common | PairCorr |
| 0.82 | HRGN | Harvard Apparatus | PairCorr |
| 0.9 | ZIVO | Zivo Bioscience | PairCorr |
| 0.7 | KRBP | Kiromic Biopharma | PairCorr |
| 0.78 | LADX | LadRx | PairCorr |
| 0.64 | MTVA | MetaVia Symbol Change | PairCorr |
| 0.75 | NEXI | Neximmune | PairCorr |
| 0.84 | OKUR | OnKure Therapeutics, Symbol Change | PairCorr |
Moving against Orgenesis OTC Stock
| 0.81 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.78 | EPRX | Eupraxia Pharmaceuticals | PairCorr |
| 0.69 | VAXX | Vaxxinity | PairCorr |
| 0.62 | FBIOP | Fortress Biotech Pref | PairCorr |
| 0.6 | EVLO | Evelo Biosciences | PairCorr |
| 0.55 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.53 | CEROW | CERo Therapeutics Symbol Change | PairCorr |
| 0.77 | LBPH | Longboard Pharmaceuticals | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Orgenesis OTC Stock performing well and Orgenesis OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Orgenesis' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| TFFP | 8.18 | (3.43) | 0.00 | (2.64) | 0.00 | 11.11 | 95.77 | |||
| ONCR | 8.13 | (2.10) | 0.00 | 1.36 | 0.00 | 10.00 | 120.67 | |||
| QNRX | 5.91 | 0.38 | 0.06 | 0.41 | 5.49 | 16.07 | 74.46 | |||
| APGN | 5.12 | 0.11 | 0.01 | (0.17) | 5.50 | 7.89 | 58.79 | |||
| AVTE | 2.40 | 0.47 | 0.19 | 5.91 | 2.01 | 5.58 | 19.11 | |||
| ADAG | 3.92 | 0.07 | 0.01 | (0.50) | 5.27 | 7.34 | 41.45 | |||
| ACRV | 2.52 | (0.16) | 0.00 | (0.08) | 0.00 | 4.83 | 19.02 | |||
| RZLT | 2.65 | (0.17) | 0.00 | (0.48) | 0.00 | 5.54 | 16.29 | |||
| ANTX | 2.59 | 0.30 | 0.10 | 0.31 | 2.26 | 6.34 | 28.89 |
View Orgenesis Related Equities
| Risk & Return | Correlation |
Orgenesis Corporate Management
Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Victor Miller | Chief Officer | Profile | |
| Osher Rheinisch | General Officer | Profile | |
| Neil CPA | S CFO | Profile | |
| Shimon Hassin | Chief Officer | Profile | |
| Efrat Kunik | Chief Officer | Profile | |
| Pierre Lammeretz | Interim Officer | Profile | |
| Evan Fishman | Chief Officer | Profile |
Still Interested in Orgenesis?
Investing in delisted otcs can be risky, as the otc stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.